EUCTR2013-001267-23-HU进行中（未招募）不适用
Open label multicentric study to evalute the safety and efficacy of CitrokalciumD 300 mg/300 NE tablets in patients assessed deficiency for supplementation of calcium and vitamin D. - Study to evaluate the safety and efficacy of the combination of calciumcitrate and vitamin D
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- postmenopausal women in age of 40-70
- •- 25(OH)-D szint < 75 nmol/ml (<30 ng/ml)
- •- average dietary calcium intake < 700 mg,
- •- ICF signed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
排除标准
- •- hypercalcaemia/ se Ca levels out of 2.20-2.60 mmol/L range
- •- or anamnestic or renal disorder of calcium hoemostatis that may interfere with the treatment
- •- other calcium of vitamin D therapy with the last 2 month over certain limits of dosages
研究者
相似试验
尚未招募
4 期
A clinical trial to study the effects of three drugs, Olmesartan Medoxomil, Chlorthalidone and Cilnidipine Tablet in treatment of essential high blood pressure in IndiaCTRI/2019/01/016858Sun Pharma Laboratories Limited
招募中
4 期
A clinical study to assess safety and effectiveness of Dalfampridine ER tablets for walking improvement in patients with Multiple Sclerosis in IndiaCTRI/2019/01/016948Sun Pharma Laboratories Limited
进行中（未招募）
1 期
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasisPsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2016-003046-87-PLAbbVie Deutschland GmbH & Co. KG2,200
进行中（未招募）
1 期
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasisEUCTR2016-003046-87-PTAbbVie Deutschland GmbH & Co. KG2,200
进行中（未招募）
1 期
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasisPsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2016-003046-87-ATAbbVie Deutschland GmbH & Co. KG2,200